医学
丛集性头痛
维拉帕米
特里普坦
重症监护医学
苏马曲普坦
神经学
叙述性评论
偏头痛
麻醉
内科学
精神科
受体
钙
兴奋剂
作者
Ildefonso Rodríguez‐Leyva,Maria-Karina Vélez-Jiménez,Silvia Garcı́a,Juan Nader-Kawachi,Adriana Patricia Martínez-Mayorga,Agustín Melo-Carrillo,Humberto Juárez-Jiménez,Marco Antonio Martínez-Gurrola,Manuel Gudiño-Castelazo,Erwin Chiquete,Jorge Villareal-Careaga,Alejandro Marfil,Paul David Uribe-Jaimes,Rubén Dario Vargas-García,Miguel Ángel Collado-Ortiz,Daniel San-Juan
标识
DOI:10.3389/fpain.2023.1265540
摘要
Cluster headache (CH) is the most common and devastating autonomic headache with multiple and recent advances in treatment. However, it usually goes unrecognized and is found to have a delayed and inappropriate treatment. This paper aims to review the current therapeutic options for patients with CH. We conducted a narrative literature review on the treatments available for this condition using the American Academy of Neurology (AAN) classification of therapeutic evidence. We found effective and safe pharmacological and non-pharmacological therapies with heterogeneity of clinical trial designs for patients with CH, and they are divided into three phases, namely, transitional, acute, and preventive interventions. Prednisone (A) is the most studied treatment in the transitional phase; acute attacks are treated using triptans (A), oxygen (A), and non-invasive transcutaneous vagal nerve stimulation (A). Verapamil (A) and monoclonal antibodies (possible A) are considered the first options in preventive treatments, followed by multiple pharmacological and non-pharmacological options in prophylactic treatments. In conclusion, numerous effective and safe treatments are available in treating patients with episodic, chronic, and pharmacoresistant CH according to the clinical profile of each patient.
科研通智能强力驱动
Strongly Powered by AbleSci AI